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The World Health Organization (WHO) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) launched their 
‘3 by 5’ initiative in December 2003. The principal aim was 
to mobilise the world to provide highly active antiretroviral 
therapy (HAART) to 3 million people living with HIV/AIDS in 
low- and middle-income countries by the end of 2005.1 By June 
2005 approximately 1 million people were receiving HAART in 
these countries, giving an estimated average coverage rate of 
15%.  Of an estimated 600 000 children in sub-Saharan Africa 
who required HAART, less than 5% were receiving therapy.2
Consequently, the United Nations Children’s Emergency Fund 
(UNICEF) along with the WHO and UNAIDS have begun 
to mobilise global forces to intensify perinatal prevention 
programmes, and extend care, particularly in the provision 
of co-trimoxazole prophylaxis to HIV-exposed children and 
HAART to all infected children in poor countries.3
From 1996 onwards triple combination antiretroviral (ARV) 
therapy has been used to treat HIV-infected children.4,5 Since 
then a large body of research has been published attesting 
to the benefits of HAART in children. Although in general 
virological control has been more difficult to achieve in 
children compared with adults, the risks of progression to 
end-stage disease or AIDS and death have been significantly 
attenuated in children treated with HAART.4,5 Furthermore, 
improvements in growth and body composition parameters, 
reduced frequency and severity of infectious complications, 
decreased hospitalisation rates and reversal or prevention 
of organ-specific damage have been achieved.6-9 Long-term 
survival is possible and some perinatally infected children 
have already reached their second or third decade of life.10,11
Research has also documented some concerns associated with 
HAART including the overall negative impact of HIV infection 
on quality of life among children, emergence of viral resistance, 
long-term metabolic complications, and the challenges of 
managing these problems.10,12
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Objective. To describe the response of children during their first 
year on highly active antiretroviral therapy (HAART). 
Design. Retrospective, descriptive.
Setting. Tertiary, referral hospital.
Subjects. All HIV-infected children commenced on HAART 
from 1 August 2002 until 31 December 2004.
Outcome measures. Children were retrospectively restaged 
using the WHO 4-stage clinical classification and CDC 
immunological staging system. After commencing HAART, 
patients were assessed at monthly intervals for the first 6 
months and thereafter mostly 3-monthly. Baseline and 6-
monthly CD4 counts and viral loads were performed.   
Results. Of 409 children commenced on HAART, 50.6% were 
< 2 years old, 62.7% had severe clinical disease and 76.6% had 
severe immune suppression. After 1 year, 65.8% were alive and 
continued HAART at the hospital, 11.2% had been transferred 
to another antiretroviral site, 15.4% had died, 4.6% were lost 
to follow-up and treatment had been discontinued in 2.9%. 
Kaplan-Meier survival estimate for 407 children at 1 year was 
84% (95% confidence interval (CI) 80 - 87%). On multivariate 
analysis, survival was adversely affected in children with 
WHO stage 4 v. stage 2 and 3 disease (adjusted hazard ratio 
(HR): 5.26 (95% CI 2.25 - 12.32), p = 0.000), age < 12 months 
(adjusted HR: 2.46 (95% CI 1.48 - 4.09), p = 0.001) and CD4 
absolute count (per 100 cell increase) (adjusted HR: 0.93 (95% 
CI 0.88 - 0.98), p = 0.013). In a separate multivariate model 
including only children with an initial viral load (N = 367), 
viral load  1 million copies/ml (adjusted HR: 1.84 (95% CI 
1.03 - 3.29)) and taking a protease inhibitor (PI)-based regimen 
(adjusted HR: 2.25 (95% CI 1.10 - 4.61)) were additionally 
independently associated with poorer survival; however, 
young age was not a significant predictor of mortality, after 
adjusting for viral load (p = 0.119). After 1 year of HAART 
184/264 (69.7%) of children had a viral load < 400 copies/ml. 
Comparative analysis showed significant improvements in 
growth, immunological status and virological control. 
Conclusion. HAART can improve the health of many HIV-
infected children with advanced disease, including those aged 
less than 2 years in resource-limited settings. 
S Afr Med J 2006; 96: 988-993.
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Several studies on paediatric ARV treatment programmes 
in middle- and low-income countries have documented 
favourable responses to HAART.13-16 At Red Cross War 
Memorial Children’s Hospital (RCH) a donor-funded ARV 
treatment programme for children was started in August 2002. 
Initial experience of this programme was reported on in 2004.17
Between February and November 2004, after the Western 
Cape province of South Africa began providing HAART to 
public sector patients, the donor-funded programme was 
fully integrated with the provincial programme. At the end 
of March 2006 RCH was therefore one of 37 accredited public 
sector institutions in the Western Cape managing children on 
HAART. At the time, 16 300 patients were receiving HAART 
in the province of whom 2009 (12.3%) were children. In this 
report we describe the response of children during their first 
year on HAART at our institution.
Methods
This retrospective study describes a public sector ARV 
treatment programme for HIV-infected children. The study 
took place at Red Cross War Memorial Children’s Hospital, 
a tertiary referral hospital affiliated to the University of 
Cape Town. All children who started treatment between 1 
August 2002 and 1 December 2004 were included. The study 
documented the outcomes of children during their first year on 
HAART. The Research Ethics Committee of the University of 
Cape Town approved the study.
Children were selected to start HAART according to 
established clinical and immunological criteria. The first 122 
children were enrolled according to criteria derived from 
the Paediatric European Network for the Treatment of AIDS 
(PENTA) recommendations. Briefly, children with Centers 
for Disease Control (CDC) clinical category C or immune 
category 3 disease and those with CDC clinical category B 
disease plus a low CD4 percentage (< 20% if < 12 months 
old or < 15% if > 12 months old) qualified for treatment and 
were considered for enrolment.18 The remaining 287 children 
were enrolled according to criteria derived from the WHO’s 
2003 recommendations for children. Children with modified 
WHO clinical stage 2 or 3 disease or a low CD4 percentage 
irrespective of disease stage (< 20% if < 18 months old or < 
15% if > 18 months old) qualified for HAART.19 In addition to 
the clinical and/or immunological criteria all children were 
required to have an identifiable caregiver who could take 
responsibility for the administration of the medication.
Triple combination ARV therapy comprising of 2 nucleoside 
reverse transcriptase inhibitors (NRTIs) plus either a non-
nucleoside reverse transcriptase inhibitor (NNRTI) or 
a protease inhibitor (PI) was administered according to 
conventional paediatric dosing recommendations.20 The 
choice of individual drugs was determined by funding 
constraints, availability of home refrigeration required to 
store temperature-sensitive drug formulations, and previous 
exposure to perinatal nevirapine. Children who had been 
exposed to perinatal nevirapine were given a PI-based regimen 
in keeping with the national treatment guidelines of South 
Africa.21 The monitoring plan included monthly clinical 
assessments for the first 6 months of therapy and thereafter 
mostly 3-monthly reviews, baseline and 6-monthly CD4 counts 
and viral loads (due to financial constraints, the viral load at 6 
months was omitted in the first 122 children unless they were 
enrolled in parallel research studies), and regular biochemical 
and haematological evaluations. 
For the purpose of this analysis, all children were 
retrospectively re-staged at the time of starting HAART 
according to the latest WHO 4-stage clinical classification and 
the CDC immunological staging system.22,23  Weight-for-age, 
height-for-age and weight-for-height z-scores were calculated 
using EpiInfo 2000, version 1.0, Division of Surveillance and 
Epidemiology, CDC, Atlanta, Georgia. Moderate underweight, 
stunting and wasting were defined as weight-for-age z-score 
(WAZ) < -2, height-for-age z-score (HAZ) < -2 and weight-for-
height z-score (WHZ) < -2 respectively. Severe underweight, 
stunting and wasting were defined as WAZ < -3, HAZ < 
-3 and WHZ < -3 respectively.24 Data were analysed using 
Stata version 8.0, College Station, Texas, USA and StatsDirect 
software, version 2.5.5, 2006, Cheshire, UK. The probability of 
survival was determined using Kaplan-Meier analysis and log-
rank tests were used to compare survival times between strata. 
The Cox proportional hazards model was used for multivariate 
analysis. Patient characteristics found to be associated with 
mortality (p < 0.1) on univariate analysis were included in the 
multivariate model, and removed by a backward selection 
procedure if p > 0.05. Separate models were estimated for all 
children, and on the subset on whom initial viral load was 
measured. The regimen variable (PI v. NNRTI) was then added 
to both models to assess whether regimen was independently 
associated with survival. The Wilcoxon signed ranks test was 
used to compare continuous data. The chi-square test was used 
to compare categorical data. A p-value of < 0.05 was regarded 
as statistically significant.
Results
By the end of December 2004, 409 children had been 
enrolled on the ARV treatment programme. The median 
age (interquartile range) at enrolment was 23 months (8.9, 
54.6), 207/409 (50.6%) were less than 24 months old and the 
female-to-male ratio was 182:227. Baseline clinical staging was 
available for 407 children: 3 (0.7%) had WHO stage 2 disease, 
149 (36.6%) WHO stage 3 disease and 255 (62.7%) WHO stage 4 
or advanced clinical disease. CD4 percentages and/or absolute 
counts were available for 406 children at the start of ARV 
therapy.  The median CD4 percentage (interquartile range) was 
11.7% (7, 17.3), 266/402 (66.2%) had a CD4 percentage < 15% 
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and 41/402 (10.2%) had a CD4 percentage  15%. According 
to the CDC classification 18/406 (4.4%) had no immune 
suppression (immune category 1), 77/406 (19%) moderate 
immune suppression (immune category 2) and 311/406 
(76.6%) severe immune suppression (immune category 3). At 
baseline the median viral load (interquartile range) was 380 000 
copies/ml (140 000, 1 292 000), and 111/367 (30.2%) had an 
initial viral load > 1 million copies/ml. The nutritional status 
of the children at the start of ARV therapy showed that 116/408 
(28.4%) were moderately underweight, 116/408 (28.4%) 
severely underweight, 129/406 (31.8%) moderately stunted, 
142/406 (35.2%) severely stunted, 55/390 (14.1%) moderately 
wasted and 26/390 (6.7%) severely wasted. The children were 
initiated on an ARV treatment regimen comprising two NRTIs 
plus either a PI (208/409 (50.9%)) or an NNRTI (201/409 
(49.1%)).
After 1 year on ARV therapy, 269/409 (65.8%) were alive and 
continued to be managed at RCH, 46/409 (11.2%) had been 
transferred to another ARV treatment site for continuation of 
HAART, 63/409 (15.4%) had died, 19/409 (4.6%) were lost 
to follow-up and treatment had been discontinued in 12/409 
(2.9%) because of sub-optimal adherence. The Kaplan-Meier 
survival estimate for all children (N = 407) at 1 year was 84% 
(95% confidence interval (CI) 80 - 87%). Survival for WHO 
clinical stage 2 (N = 3), stage 3 (N = 149) and stage 4 (N  = 
255) was 100%, 96% (95% CI 91 - 98%) and 77% (95% CI 71 
- 82%) respectively (Fig. 1). On univariate analysis, survival 
was adversely affected in children with WHO stage 4 v. stage 2 
and 3 disease (hazard ratio (HR): 6.19 (95% CI 2.67 - 14.36), p = 
0.000), age < 12 months (HR: 2.81 (95% CI 1.71 - 4.61), 
p = 0.000), those with a viral load  1 million copies/ml 
(HR: 2.80 (95% CI 1.63 - 4.80, p = 0.000) and those on a PI 
regimen (HR: 3.84 (95% CI 2.12 - 6.96), p = 0.000). Survival 
was unaffected by gender, CDC immunological category, 
absolute CD4 count and CD4 percentage. On multivariate 
analysis of all children, after adjusting for WHO clinical stage 
and age, the absolute CD4 count did affect survival. In a 
separate multivariate model including only children on whom 
an initial viral load was done (N  = 367), more severe WHO 
clinical stage, lower absolute CD4 count, viral load  1 million 
copies/ml and taking a PI-based regimen were independently 
associated with poorer survival; however, age was no longer a 
significant predictor of mortality (p = 0.119) (Table I).
One-year viral load results were available for 264/269 
children who continued their management at RCH throughout 
the first year on HAART.  The proportion of these children 
with a viral load less than 400 copies/ml was 184/264 (69.7%). 
A further 26/264 (9.8%) had a viral load between 400 and 5 000 
copies/ml. A more detailed analysis of the cohort after 1 year 
of HAART is presented in Table II. This analysis is confined to 
children with complete results at both baseline and 1 year, for 
each parameter evaluated.
Discussion
The treatment programme at RCH is an integral component 
of a complex network of primary, secondary and tertiary 
ARV treatment sites that was established by the HIV/AIDS 
Directorate of the Western Cape from March 2004 onwards to 
respond to the HIV epidemic among children in the province. 
Through donor funds several institutions, including RCH, 
began treating children before 2004 but all have since been 
incorporated into the provincial network.17 Central to the 
provincial response to the paediatric epidemic is a successful 
perinatal prevention programme. The perinatal programme has 
undergone significant improvement in the last few years and 
could in the foreseeable future reduce the absolute perinatal 
transmission rate to less than 5%. This should decrease the 
paediatric HIV burden and ultimately lead to improved care 
for children with established infection. The development of 
treatment sites for children has generally lagged behind adult 
care. However, this problem has largely been corrected and at 
Table I.  Predictors of death in children receiving HAART
Adjusted HR 95% CI p-value
Cox-proportional 
hazards model for 
all children (N = 407)  
  WHO stage 4 5.26 2.25 - 12.32 0.000
  Age < 12 months 2.46 1.48 - 4.09 0.001
  CD4 absolute count 
  (per 100 cell increase) 0.93 0.88 - 0.98 0.013
Cox-proportional 
hazards model for 
children on whom 
initial viral load was 
measured (N = 367)  
  WHO stage 4 3.84 1.45 - 10.20 0.007
  CD4 absolute count 
  (per 100 cell increase) 0.90 0.84 - 0.96 0.002
  Viral load  1 million 1.84 1.03 - 3.29 0.041
  PI-based regimen 2.25 1.10 - 4.61 0.026
Adjusted HR = adjusted hazard ratio;  95% CI = 95% confidence interval; PI = 
protease inhibitor.
Fig. 1. Kaplan-Meier survival estimates by WHO clinical stage.
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the end of March 2006, 37/43 (86%) ARV treatment sites in the 
province were treating children.25
This retrospective study addressed the effectiveness of 
HAART in a setting characterised by high unemployment and 
low rates of secondary school completion among caregivers.26
As with many retrospective studies some of the data were 
not available for analysis. Furthermore, children were 
retrospectively restaged using the latest WHO clinical staging 
system and the CDC immunological staging system. While 
immunological classification is based on objective criteria, 
retrospective clinical staging is dependent on the quality and 
availability of the clinical records. The latest WHO staging 
guidelines include clinical case definitions for each staging 
criterion, which does improve the objectivity of staging.22
Furthermore, the impact of HAART on the frequency and 
severity of infectious complications and on hospitalisation 
rates was not evaluated.  Despite these limitations, we believe 
that the results of this study are an accurate reflection of the 
response to HAART at our institution.    
Baseline characteristics described the clinical condition of the 
children at the time of starting HAART. Striking features were 
the high frequency of advanced, WHO clinical stage 4 disease 
(62.7%), advanced immune suppression (76.6%) and pervasive 
nutritional deficiencies. The median age of 23 months, the high 
proportion of children below 2 years of age and the adverse 
survival associated with an age of  less than 1 year reflect the 
high burden of severe disease among young children treated 
at our institution. These findings are consistent with natural 
history studies of paediatric HIV infection in Africa that have 
reported mortality rates in excess of 50% by the age of 2 years.27
In contrast, previous publications on paediatric ARV treatment 
programmes from low- and middle-income countries have 
documented limited experience with treating children less 
than 2 years of age.13,15,16  Treating young infected children 
may be particularly challenging as they often have complex 
medical problems, the state of knowledge of the use of ARVs 
in the very young is incomplete and obtaining blood samples 
for monitoring may be technically challenging. For these 
reasons health professionals have generally been reluctant to 
treat young children with HIV infection.28 Special attention is 
needed to ensure that health institutions in resource-limited 
settings are adequately capacitated to address the medical 
needs of this vulnerable group.                        
Given the severity of the clinical and immunological status 
of the children at baseline and the high proportion of young 
children in the programme, the overall estimated survival 
after 1 year of 84% (95% CI 80 - 87%) was reasonable. The 
probability of survival on HAART after 1 year in a study 
conducted in Côte d’Ivoire was 91% (95% CI 82.1 - 95.6%). In 
that study 107 children were enrolled, hence the wider 95% 
confidence interval, the median age at enrolment was 7.2 years, 
which was higher than in our study, and severe clinical disease 
was present in only 12.8%, suggesting that children enrolled in 
that study were relatively less ill at the start of HAART.13 The 
marked, but expected, predictable pattern of decline in 1-year 
survival between children with WHO stage 2 and 3 disease 
(96% (95% CI 91 - 98%)) compared with those with WHO stage 
4 disease (77% (95% CI 71 - 82%)) and the adverse effect of viral 
load  1 million on survival in our study suggests that the high 
proportion of children enrolled with severe disease adversely 
affected overall survival rates. While the Côte d’Ivoire study 
showed significantly lower survival in children with a CD4 
percentage < 5%, interestingly in our study survival was not 
associated with CD4 percent or CDC immunological category.13
However, on multivariate analysis higher absolute CD4 counts 
were independently associated with improved survival, with 
a 7% (95% CI 2 - 12%) reduction in mortality for every 100-
cell increase in CD4 count. In the present study, univariate 
Table II. Comparison of status at baseline and 1 year after commencing HAART 
Parameter Baseline 1 year p-value
Median WAZ; IQR -2.17; -3.09, -1.12 -0.93; -1.66, -0.13 0.000
  Moderate underweight 76/266 (28.6%) 42/266 (15.8%) 0.000
  Severe underweight 73/266 (27.4%) 9/266 (3.4%) 0.000
Median HAZ; IQR -2.51; -3.41, -1.72 -1.92; -2.67, -1.14 0.000
  Moderate stunting 89/264 (33.7%) 77/264 (29.2%) 0.3
  Severe stunting 89/264 (33.7%) 46/264 (17.4%) 0.000
Median WHZ; IQR -0.63; -1.77, 0.4 0.43; -0.37, 1.14 0.000
  Moderate wasting 34/254 (13.4%) 3/254 (1.2%) 0.000
  Severe wasting 18/254 (7.1%) 3/254 (1.2%) 0.000
Median CD4%; IQR 12.0; 7.2, 17.2 24.0; 18.74, 30.0 0.000
  CD4% < 15% 173/261 (66.3%) 28/261 (10.7%) 0.000
  CD4% 25% 26/261 (10.0%) 118/261 (45.2%) 0.000
Median log10 VL; IQR 5.54; 5.15, 6.08 2.6; 2.6, 3.27 0.000
  VL > 106 copies/ml 69/241 (28.6%) 3/241 (1.2%) 0.000
  VL < 400 copies/ml 0/241 168/241 (69.7%) 0.000
IQR = interquartile range; WAZ = weight-for-age z-score; HAZ = height-for-age z-score; WHZ = weight-for-height z-score; VL = viral load.
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analysis and the multivariate model on all children suggest 
that children under 1 year of age experience adverse survival. 
However, the separate multivariate model in children in whom 
an initial viral load was measured showed that after adjusting 
for viral load, age does not affect survival. This suggests that 
poorer survival in very young children is due to their more 
severe disease rather than their age per se. While univariate 
analysis and the multivariate submodel including viral load 
showed greater mortality in children receiving a PI-based 
regimen, this was not confirmed in the main multivariate 
model for all children in the study. The apparent adverse 
effect of a PI-based regimen may therefore largely be due to 
preferential administration of PIs to younger children who 
tended to have more severe disease. Alternatively, regimen 
and age were co-linear variables, which may explain why age 
was excluded and replaced with regimen in the multivariate 
submodel analysis.
Table II summarises the effect of 1 year of HAART on 
growth, immune reconstitution and viral replication in children 
for whom complete data existed. Notably, of 264 children 
who remained on HAART at RCH 69.7% had a viral load 
below 400 copies/ml. This result is consistent with published 
efficacy studies where the percentage of children with viral 
loads < 400 copies/ml varied between 63% and 87%.29 The 
future management of the 30.3% of children with detectable 
viral loads is of concern. Current national treatment guidelines 
have made provision for two rounds of ARV therapy. Beyond 
second-line therapy there is no specific recommendation for the 
provision of salvage regimens.21 This particular issue has to be 
confronted in South Africa and other middle-income countries 
where resources exist to manage patients beyond second-line 
therapy and where a sizeable proportion of children are likely 
to fail second-line therapy in the near future.           
After 1 year on HAART, 11.3% of the children had been 
transferred to another ARV treatment site for ongoing care. 
Most were referred to their local community clinics in the 
greater Cape Town region. This development represents 
another important component of the provincial paediatric 
programme, namely the provision of treatment for infected 
children at the most appropriate level within the health care 
system. Referral of clinically stable children on HAART 
to community institutions accompanied by the transfer of 
appropriate paediatric clinical skills is a necessary strategy 
in countries with high HIV prevalence rates. This approach 
will alleviate the congestion experienced at referral hospitals, 
allowing them to address the more technically challenging 
aspects of the disease, including children with complex 
pathology, serious infectious complications, adverse events 
including immune reconstitution inflammatory syndrome, 
and many of the younger children. The success of this 
initiative, which has gained momentum over the last year, is 
best illustrated with the official provincial statistics. At the 
end of March 2004, 78.4% (537/685) of all children treated 
with HAART in the province were managed at the three 
paediatric referral hospitals in Cape Town namely RCH, 
Groote Schuur Hospital and Tygerberg Hospital.30 At the end 
of March 2006, this figure had declined to 49.5% (995/2009) of 
the total number of children on treatment.25 Furthermore, the 
referral hospitals in Cape Town have been actively involved 
in developing the clinical capacities of health professionals at 
community institutions and providing telephonic and on-site 
consultation support to these institutions.
In conclusion, while this study has demonstrated that 
HAART is able to improve the health of many HIV-infected 
children with advanced disease, including those less than 
2 years of age in a middle-income country, it has generated 
concern about treatment beyond second-line therapy.  
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